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those using one or none (1.62, 1.01–2.6). CONCLUSION: The
medications identiﬁed were commonly used among elderly vet-
erans undergoing MOS. The use of aspirin was associated with
a decreased risk of VTE. Using more than one inappropriate drug
was associated with an increase risk of VTE.
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OBJECTIVES: SCD is an inherited disorder characterized by life-
long morbidity and reduced life expectancy. Treatments include
blood transfusion, pain medication and hydroxyurea (HU). We
analyzed treatments, outcomes and costs in the outpatient
setting. METHODS: A total of 9281 patients were identiﬁed
from the 2000–2004 Pharmetrics® Database using ICD-9 Codes
(282.41, 282.42, 282.6x). Crisis was deﬁned either by a diag-
nosis code referring to crisis (282.42, 282.62, 282.64, 282.69),
strong opioid use, ER admission or SCD hospitalization.
RESULTS: 44% of patients were younger than 16 yrs; 56% were
female. Mean age was 22(±19). Seventy-seven percent had one
or more painful crises in one year. In the HbSS subtype, 85%
had at least one crisis. Incidence and frequency of painful crises
increased by age: 70% (0–6 yrs); 75% (6–16) and 82% (>16)
and 1.0/yr, 2.4/yr and 4.7/yr, respectively. Two-thirds of adults
with Hb SS who experienced crisis received opioids compared to
22% of children, aged 0–6 with Hb SS and crisis. Thirty-seven
percent had at least one ER visit; in adult Hb SS patients more
than 50%. Average annual hospitalization rate was 32.4%, with
2.25 admissions and length of stay 6 days. Hb SS patients had
a hospitalization rate > 40%. Patients with crisis were four times
as likely as non-crisis patients to require multiple hospitaliza-
tions. Overall annual stroke rate was 3.9%; in adult HbSS
patients it was 7.2%. Hb SS children had rates of 1.13% (<6 yr)
and 4.22% (6–16 yr). Annual costs, including hospitalization
costs, ranged from $1140 in <6 yrs without crisis to $20,432 in
adults with crisis. Health cost in crisis patients were 5-fold that
of non-crisis patients. CONCLUSION: SCD has major impact
on patients’ outcomes such as pain, stroke and costs thousands
of dollars per patient per year. The incidence of crises correlates
with health care resource utilisation and cost. Treatments that
avoid crises will have positive impact on quality of life and costs.
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OBJECTIVES: Severe hemophiliacs experience frequent sponta-
neous intra-articular hemorrhages, leading to arthropathy. Until
recently, hemophilia patients with high titer inhibitors to Factor
VIII (A) or Factor IX (B) concentrate could not undergo ortho-
pedic surgery to reduce pain and bleeding because of the risk of
uncontrolled bleeding during and following surgery. The recent
availability of recombinant activated factor VII (rFVIIa) has
made these surgeries possible. This analysis adopts a US payer
perspective to estimate the lifetime costs of 9 elective orthopedic
surgeries (e.g., joint replacements, osteotomies, arthodesis) with
rFVIIa in hemophilia patients with high-titer inhibitors and 
frequent bleeding episodes. METHODS: A literature-based
Markov model was developed to compare the lifetime costs of 2
cohorts of eligible patients (aged 25 yrs and followed for 65 yrs),
one undergoing orthopedic surgery and the other not undergo-
ing surgery. Surgery costs included perioperative rFVIIa therapy,
hospitalization, rehabilitation, and repeat procedures. The cost
of managing individual bleeding episodes was obtained from
published literature. RESULTS: Surgery was estimated to cost
anywhere from $562,000 for ankle distal tibial osteotomy to
$938,000 for total knee replacement. However, each surgery was
predicted to reduce remaining lifetime bleeding episodes at the
affected joint from 405 to 64 per patient. Surgery resulted in 
a discounted remaining lifetime net savings of $1,872,000 for
total knee replacement to $2,218,000 for ankle distal tibial
osteotomy. The initial surgery cost was offset in 5–10 years. If
the rate of bleeding episodes increases at a rate of 5% per year
in those not receiving surgery (up to a maximum of 22 bleeds
per year), the net savings were >$4.6 million across all surgeries.
Prophylaxis regimen, survival rates, pre-surgery bleeding fre-
quency, patient weight, and the repeat surgery rate were sensi-
tive model variables. CONCLUSION: Orthopedic surgery in
hemophilia patients with inhibitors managed with rFVIIa
appears to be cost saving in the long term.
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OBJECTIVES: Studies have reported dose utilization ratios for
epoetin alfa (EPO) versus darbepoetin alfa (DARB) ranging from
126 : 1 (units : mcg) to 400 : 1. We sought to determine the rela-
tive dosages at which EPO and DARB are utilized in clinical
practice for Department of Defense (DoD) beneﬁciaries.
METHODS: Study patients included adults newly started on ery-
thropoiesis-stimulating agents (ESAs) from October 1, 2005 to
June 30, 2006 with at least 3 consecutive prescriptions for EPO
or DARB. Prescription information was obtained from DoD’s
Prescription Data Transaction Service Data Warehouse. The Mil-
itary Health System Management Analysis and Reporting Tool
was used to identify study patients with primary or secondary
ICD-9-CM codes consistent with chronic kidney disease or
malignancy. Patients were excluded if they received both EPO
and DARB during the study period or had both nephrology and
oncology indications for ESA therapy. Dose utilization ratios
were calculated by dividing weekly EPO doses by weekly DARB
doses (units : mcg). RESULTS: Overall, 914 patients met study
criteria (mean age 68 years; 55% female) with 36% receiving
ESA therapy for an oncology indication and 34% for a nephrol-
ogy indication. Patients received a total of 2366 ESA prescrip-
tions (59% for EPO and 41% for DARB). The median EPO and
DARB doses were 25,452 units per week (interquartile range
10,766–41,745) and 98 mcg per week (interquartile range
42–133), respectively. The median dose utilization ratios for EPO
to DARB were 260 : 1 for all patients, 370 : 1 for oncology
patients, and 243 : 1 for nephrology patients. Oncology patients
received higher ESA doses than nephrology patients (p < 0.001,
Mann-Whitney U test). CONCLUSION: The dose utilization
ratio of EPO to DARB was higher for oncology patients (370 :
1) compared to nephrology patients (243 : 1). Signiﬁcantly higher
ESA doses were used for oncology patients compared to nephrol-
ogy patients.
